Mercaptopurine Silver Pharma (Mercaptopurine Monohydrate)

After oral absorption, mercaptopurine is metabolised to thio‑inosine monophosphate, which blocks de novo purine synthesis and incorporates into DNA and RNA. This interferes with nucleic‑acid formation, causing cytotoxicity in rapidly dividing cells and suppressing immune‑cell proliferation.

The dose is individualized and set by the prescribing clinician based on the patient’s age, weight, disease indication, and laboratory parameters such as TPMT activity. No fixed regimen is provided here; dosing decisions are made by the treating physician.

Mercaptopurine’s pregnancy category is not definitively established. It should be used only when the potential therapeutic benefit justifies the possible risk to the fetus. Breastfeeding is generally discouraged because the drug can be excreted in milk; consult a healthcare professional for personalized advice.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and necessary import documentation.

The most common alternative is azathioprine, another thiopurine. Both share similar mechanisms, but mercaptopurine is often preferred for certain leukemias because it provides more direct antineoplastic activity, whereas azathioprine is primarily used as an immunosuppressant in transplant and autoimmune settings.

Store the product at temperatures below 25 °C, in its original packaging, protected from moisture and direct light. Keep the container tightly closed and out of reach of children. Do not refrigerate unless the label specifically indicates otherwise.

The medication is taken orally, usually with a glass of water. It may be taken with or without food, but consistent administration with respect to meals helps maintain stable absorption. Follow the prescribing clinician’s instructions regarding timing and any dietary considerations.

Serious risks include severe bone‑marrow suppression leading to pancytopenia, hepatotoxicity, pancreatitis, life‑threatening infections due to immunosuppression, hypersensitivity reactions such as Stevens‑Johnson syndrome, and the rare development of secondary malignancies.

Patients with known hypersensitivity to mercaptopurine or any of its excipients should avoid it. Those with severe hepatic impairment, active uncontrolled infections, or pre‑existing severe bone‑marrow suppression should not be started on the drug without careful specialist evaluation.